Skip to main content
. 2020 Nov 13;3:677. doi: 10.1038/s42003-020-01404-3

Fig. 7. Macitentan impairs metastatic spread by interfering with the ETAR-miR-200b/c-ZEB1 circuit.

Fig. 7

a, b Female nude mice are i.p. injected with SKOV3, OVCAR-3, A2780, or A2780 CIS cells and treated with vehicle (Ctr) or MAC (30 mg/kg oral daily) for 5 weeks. Graph represents the number of visible metastasis. Columns show the mean ± SD (*p < 0.001 vs. Ctr). c WB analysis of the indicated proteins in lysates from i.p. nodules of three representative (M1-M3) SKOV3, OVCAR-3, A2780, and A2780 CIS xenografts treated as in a. β-actin is used as loading control. d ZEB1, Vimentin, and E-cadherin gene expression in i.p. nodules of SKOV3, OVCAR-3, A2780, and A2780 CIS xenografts treated as in a is analyzed by qRT-PCR and normalized to cyclophilin-A. Values are the mean ± SD (*p < 0.004 vs. Ctr). e miR-200b/c expression in i.p. nodules of SKOV3, OVCAR-3, A2780, and A2780 CIS xenografts treated as in a is analyzed by qRT-PCR. U6 is used to normalize. Values are the mean ± SD (*p < 0.006 vs. Ctr). f The binding of ZEB1 on miR-200b promoter region and on a region -1900 bp upstream the miR-200b TSS site (lacking ZEB1 binding sites, negative control for non-specific enrichment) is analyzed by ChIP assay followed by PCR in SKOV3 xenografts treated as in a. Anti-IgG mouse (IgGM) Ab is used as control for all ChIP reactions. g Schematic model of a regulatory circuit established by ETAR-miR-200b/c-ZEB1 to control metastatic progression that is activated by ET-1 and inhibited by macitentan.